VERV’s VERVE-102 showed an impressive 69% LDL-C reduction in its early Phase 1b data. Click here to find out why I rate VERV ...

Precision BioSciences stock soars 24% as the FDA grants the Fast Track designation to its PBGENE-HBV gene therapy for potentially curing chronic hepatitis B.

Precision BioSciences (DTIL) announced that the FDA has granted fast track designation for PBGENE-HBV, the company’s lead wholly owned in vivo ...

SynOx Therapeutics Limited (“SynOx”), a late-stage clinical biopharmaceutical company developing of emactuzumab for Tenosynovial Giant Cell Tumours (TGCT), today announced that the United States Food ...

Arcturus Therapeutics Holdings Inc. ARCT announced that the FDA has granted a Fast Track designation to its self-amplifying ...

Verve Therapeutics (NASDAQ:VERV) stock gains as the company wins the FDA fast track designation for VERVE-102, a cholesterol ...

Verve Therapeutics has won U.S. Food and Drug Administration fast-track designation for its Verve-102 gene-editing drug targeting a cholesterol driver of atherosclerosis.

Arcturus Therapeutics Holdings has won U.S. Food and Drug Administration fast-track designation for its ARCT-2304 pandemic flu vaccine candidate.

The FDA granted Breakthrough Therapy designation to IDE196 for the neoadjuvant treatment of primary uveal melanoma when ...

Enter psychedelics like ketamine, psilocybin, and MDMA, which are being explored as tools to access and process these buried ...

BIIB080 marks the first antisense oligonucleotide targeting tau to enter clinical development for the treatment of Alzheimer ...